Biocon Biologics has one of the deepest portfolios of biosimilars in the industry, spanning across insulin, monoclonal antibodies and conjugated recombinant proteins. Our long-term investments in R&D have yielded several molecules in diabetes, oncology, immunology, ophthalmology and bone health of which eight have been already commercialized in markets globally.

The biosimilars that we are developing can potentially address a USD 70 billion global market opportunity by FY27.

A robust portfolio with both depth and breadth across therapeutic areas mean Biocon Biologics has new product launches planned almost every year through 2030.

1 Clinical to BLA Review;  2 Pre-Clinical

Setting New Benchmarks for Worldwide Biosimilars Industry

Biocon Biologics has achieved many global ‘firsts’ and set new benchmarks for the global biosimilars industry. In July 2021, we were the first to get an interchangeable designation for our biosimilar Insulin Glargine (Semglee) from the U.S. FDA. This is a testament to the Company’s scientific excellence and robust quality comparability data.

We were also the first company to receive U.S. FDA approvals for biosimilar Trastuzumab in 2017 and biosimilar Pegfilgrastim in 2018.

*Co-developed with Viatris.

Expanding Our Portfolio with Vaccines for Infectious Diseases

Even as we have continued to strengthen our biosimilars portfolio to broaden access to patients, our investments so far have focused on debilitating non-communicable diseases.

The COVID-19 pandemic and the ensuing crisis exposed the inequity in access to global health, particularly when combating communicable diseases. Biocon Biologics has demonstrated scientific credibility, global-scale manufacturing and a proven track record of commercial success across geographies. Our strategy of “Expanding on Adjacencies” is about leveraging our strengths to invest in growth drivers for the future.

The strategic alliance with Serum Institute Life Sciences (SILS) is an important step in that direction as we expand into developing vaccines as a potential future growth driver. The ‘asset-light’ deal structure of this alliance with the world’s largest vaccine maker has ensured that Biocon Biologics has access to assured vaccine manufacturing capacity for the next 15 years.

Upon closing of the transaction, Biocon Biologics will get committed access to a 100 million doses of vaccines annually for ~15 years along with commercialization rights to the entire vaccines portfolio of SILS.